Current Status of Financing and Reimbursement of Trastuzumab (Herceptin®) for Adjuvant and Advanced Therapy of Breast Cancer in Germany

Publisher： Karger

E-ISSN： 1661-3805|1|2|86-94

ISSN： 1661-3791

Source： Breast Care, Vol.1, Iss.2, 2006-05, pp. : 86-94

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant Antibody Therapy with Trastuzumab in Early Breast Cancer

By  

Breast Care, Vol. 1, Iss. 4, 2006-09 ,pp. : 252-255

Karger

Access to resources Recommend Favorite

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 78-84

Karger

Access to resources Recommend Favorite

Therapy with Lapatinib: Current Status in Women with Advanced Breast Cancer

By  

Breast Care, Vol. 2, Iss. 2, 2007-04 ,pp. : 76-80

Karger

Access to resources Recommend Favorite

Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 406-410

Karger

Access to resources Recommend Favorite

Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts

By  

Breast Care, Vol. 11, Iss. 4, 2016-07 ,pp. : 275-281

Karger

Access to resources Recommend Favorite